Trials / Unknown
UnknownNCT04214717
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
Study of Dendritic Cell-activated Cytokine-induced Killer Cell Combined With Chemotherapy for Advanced Solid Tumor
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Yantai Yuhuangding Hospital · Academic / Other
- Sex
- All
- Age
- 10 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
Detailed description
Patients in group A will receive 4 cycles of DC-CIK treatments within 8 months. Patients in group B will have no immunotherapy. Chemotherapy are available in both groups.The investigators want to evaluate the efficacy of combination of DC-CIK with chemotherapy in patients with treatment-refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | DC-CIK combined with Chemotherapy | Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months. |
| DRUG | Chemotherapy | Patients will only receive Chemotherapy. |
Timeline
- Start date
- 2019-12-31
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2020-01-02
- Last updated
- 2023-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04214717. Inclusion in this directory is not an endorsement.